Skip to content

Press Releases

 
Press Releases
All Releases
Oct 1, 2014
- ETC-1002-008 study meets primary endpoint - - LDL-cholesterol lowering significantly greater with ETC-1002 than ezetimibe - - ETC-1002 appears to be safe and well tolerated - Conference Call and Webcast on Wednesday, October 1, 2014 at 4:30 p.m. Eastern T...
Sep 22, 2014
Webcast on Friday, September 26, 2014 at 8:30 a.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR) a clinical-stage emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol ...
Aug 12, 2014
Conference Call and Webcast on Tuesday, August 12, 2014 at 4:30 p.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ:ESPR) a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipo...
Aug 5, 2014
Conference Call and Webcast on Tuesday, August 12, 2014 at 4:30 p.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR) a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lip...
Jul 24, 2014
ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hyperchole...
Jul 16, 2014
ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announ...
Jun 26, 2014
ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announ...
Jun 17, 2014
Presentation on Tuesday, June 24 at 12:30 p.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics Inc. (NASDAQ: ESPR), a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) ...
May 29, 2014
Presentation and Webcast on Thursday, June 5 at 2:30 p.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics Inc. (NASDAQ: ESPR), a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol...
May 12, 2014
Conference Call and Webcast Today, Monday, May 12, 2014 at 4:30 p.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density li...
May 6, 2014
Presentation and Webcast on Tuesday, May 13 at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced the Company will present at the 2014 Bank of America Merrill Lynch Healthcare Conference in La...
May 5, 2014
Conference Call and Webcast on Monday, May 12, 2014 at 4:30 p.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced that it will host a conference call and webcast to report first quarter 2014 operational and financial results...
May 1, 2014
ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the company will deliver three posters featuring ETC-1002 Phase 2 clinical results at the 2014 Annual Scientific Sessions of the National Lipid Association in Orlando, Fla. The posters provide additional information fro...
Mar 24, 2014
Presentation and Webcast Held Friday, March 28 at 2:30 p.m. Eastern Time PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholester...
Mar 5, 2014
Conference Call and Webcast Today, Wednesday, March 5, 2014, at 4:30 p.m. Eastern Time PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-densit...
= add release to Briefcase